Comparison of Central and Peripheral Administration of C75 on Food Intake, Body Weight, and Conditioned Taste Aversion

  1. Deborah J. Clegg1,
  2. Matt D. Wortman1,
  3. Stephen C. Benoit1,
  4. Charles C. McOsker2 and
  5. Randy J. Seeley1
  1. 1Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio
  2. 2Procter & Gamble Pharmaceuticals, Cincinnati, Ohio

    Abstract

    Mice respond to fatty acid synthase (FAS) inhibitors by profoundly reducing their food intake and body weight. Evidence indicates that the central nervous system (CNS) may be the critical site of action; however, a peripheral contribution cannot be ruled out. We compared doses of the FAS inhibitor C75 in the CNS (third ventricle [i3vt]) and periphery (intraperitoneal [IP]) to reduce food intake and body weight in rats. Centrally, the threshold dose was 3 μg, whereas a dose of 10 mg/kg was required peripherally. Such data argue for FAS activity in the CNS as a potent target for the actions of C75. To control for nonspecific effects of FAS inhibition, we compared C75 administration in two models of illness, conditioned taste aversion and need-induced sodium appetite. Our results suggest the anorexia produced by IP C75 is accompanied by visceral illness, whereas the anorexia produced by i3vt is not. In addition, we placed animals in an indirect calorimeter after an IP injection of C75. We found that consistent with behavioral measures of visceral illness, peripheral C75 reduced heat expenditure and resulted in animals losing less weight than fasted control animals, suggesting that peripherally administered C75 has aversive properties. Understanding the mechanisms by which FAS inhibition in the CNS reduces food intake could lead to specific targets for the manipulation of energy balance and the treatment of obesity.

    Footnotes

    • Address correspondence and reprint requests to Deborah J. Clegg, Department of Psychiatry, Box 670559, University of Cincinnati Medical Center, Cincinnati, OH 45267-0559. E-mail: debbie.clegg{at}uc.edu.

      Received for publication 13 March 2002 and accepted in revised form 6 August 2002.

      C.C.M. is employed by Proctor & Gamble Pharmaceuticals, which conducts research on pharmaceuticals related to the treatment of obesity and diabetes. R.J.S. receives research support from Procter & Gamble for research in the area of body weight regulation.

      CNS, central nervous system; CAT, conditioned taste aversion; FAS, fatty acid synthase; i3vt, third ventricle; IP, intraperitoneal.

    « Previous | Next Article »Table of Contents